Experience

Oncodrug Ltd

• Research Services
• 1 - 100 Employee

• Principal Chemist

  • Nov 2022 - Present

  Highly accomplished medicinal chemistry leader, project, lab manager in both academic and industry settings, and acting operational manager. Experienced across many disease indications and a range of regulatory proteins. Currently, leading the medicinal chemistry strategy for a key oncology target. Strengths in leadership, drug design, internal, external and collaborative project and line management clearly demonstrated by the successful delivery of candidates towards clinical development. Highly accomplished medicinal chemistry leader, project, lab manager in both academic and industry settings, and acting operational manager. Experienced across many disease indications and a range of regulatory proteins. Currently, leading the medicinal chemistry strategy for a key oncology target. Strengths in leadership, drug design, internal, external and collaborative project and line management clearly demonstrated by the successful delivery of candidates towards clinical development.



Cancer Research UK Manchester Institute

• United Kingdom
• Research Services
• 100 - 200 Employee

• Medicinal Chemist

  • Mar 2010 - Dec 2022

  Presently working as lead chemist on a successful collaborative program with GSK. Key skill sets employed include leadership, project management- internal and external, teamwork, design and synthesis of medicinal chemistry targets. Presently working as lead chemist on a successful collaborative program with GSK. Key skill sets employed include leadership, project management- internal and external, teamwork, design and synthesis of medicinal chemistry targets.



Evotec, 112 Milton Park, Abingdon, UK.

• 112 Milton Park, Abingdon, UK

• Lead Chemist

  • Jan 2002 - Mar 2010

  Medicinal Chemist at Evotec, Abingdon where I gained a substantial amount of experience working as a lead chemist on collaborative projects with Boehringer Ingelheim and Novartis alongside internal programs. I have been in the position of working on GPCRs and ion channels for a range of disease areas which included pain and inflammation, obesity and schizophrenia. Patents: 1) New bradykinin b1 antagonists. Madden, J.; Hallet, D.J.; Parkes, A.; Raoof, A.; Wang, X. WO2010020556 A1. 2) Triazine- oxadiazoles. Barker, O.; Bentley, J.M.; Bock, M.G.; Cain, T.; Chovatia, P.; Dod, J.R.; Eustache, F.; Gleave, L.; Hargrave, J.; Heifetz, A.; Law, R.; Raoof, A.; Willows, D. WO20150025057. Show less